GRM5 and fragile X syndrome: mGluR studies have been extended successfully to mouse models of FXS (Dolen et al., 2010, , 2007), although so far two different mGlu5 inhibitors have failed to benefit FXS patients in clinical trials (Scharf et al., 2015).